28109920|t|Myocardial Blood Flow and Inflammatory Cardiac Sarcoidosis
28109920|a|This study sought to evaluate the effects of inflammatory sarcoid disease on coronary circulatory function and the response to immune-suppressive treatment. Although positron emission tomography assessment of myocardial inflammation is increasingly applied to identify active cardiac sarcoidosis, its effect on coronary flow and immune-suppressive treatment remains to be characterized. Thirty-two individuals, who were referred for positron emission tomography / computed tomography, were evaluated for known or suspected cardiac sarcoidosis applying (18)F-fluorodeoxyglucose to determine inflammation and (13)N-ammonia to assess for perfusion deficits following a high-fat / low-carbohydrate diet and fasting state >12 h to suppress myocardial glucose uptake. Inflammation was quantified with standardized uptake value and regional myocardial blood flow at rest and during regadenoson - stimulated hyperemia was determined in ml/g/min. Positron emission tomography studies were repeated in 18 cases with a median follow-up of 2.5 years (interquartile range [IQR]:1.3 to 3.4 years). Twenty-five exams had normal perfusion but evidence of regional inflammation (group 1), and 21 exams presented a regional perfusion deficit associated with inflammation (group 2). Median myocardial blood flow did not differ between inflamed and noninflamed myocardium in both groups (0.86 ml/g/min [IQR: 0.66 to 1.11 ml/g/min] vs. 0.83 ml/g/min [IQR: 0.64 to 1.12 ml/g/min] and 0.74 ml/g/min [IQR: 0.60 to 0.93 ml/g/min] vs. 0.77 ml/g/min [IQR: 0.59 to 0.95 ml/g/min], respectively). As regards median hyperemic myocardial blood flows, they were significantly lower in the inflamed than in the remote regions in group 1 and 2 (2.31 ml/g/min [IQR: 1.81 to 2.95 ml/g/min] vs. 2.70 ml/g/min [IQR: 2.07 to 3.30 ml/g/min] and 1.61 ml/g/min [IQR: 1.17 to 2.18 ml/g/min] vs. 1.94 ml/g/min [IQR: 1.49 to 2.39 ml/g/min]; p < 0.001, respectively). Immune-suppression -mediated decrease in inflammation was associated with preserved myocardial flow reserve (MFR) at follow-up, whereas MFR significantly worsened in regions without changes or even increases in inflammation (median Δ MFR: 0.07 [IQR: -0.29 to 0.45] vs. -0.24 [IQR: -0.84 to 0.21]; p < 0.001). There was an inverse correlation between pronounced alterations in myocardial inflammation (Δ regional myocardial volume with standardized uptake value >4.1) and Δ MFR (r = -0.47; p = 0.048). Sarcoid -mediated myocardial inflammation is associated with a regional impairment of coronary circulatory function. The association between immune-suppressive treatment -related alterations in myocardial inflammation and changes in coronary vasodilator capacity suggests direct adverse effect of inflammation on coronary circulatory function in cardiac sarcoidosis.
28109920	0	21	Myocardial Blood Flow	T042	C2986786
28109920	26	38	Inflammatory	T046	C0021368
28109920	39	58	Cardiac Sarcoidosis	T047	C0392077
28109920	64	69	study	T062	C0008972
28109920	93	100	effects	T080	C1280500
28109920	104	116	inflammatory	T046	C0021368
28109920	117	132	sarcoid disease	T047	C0036202
28109920	136	156	coronary circulatory	T042	C0010067
28109920	157	165	function	T169	C0542341
28109920	186	214	immune-suppressive treatment	T061	C0021079
28109920	225	253	positron emission tomography	T060	C0032743
28109920	268	291	myocardial inflammation	T047	C0027059
28109920	328	354	active cardiac sarcoidosis	T047	C0392077
28109920	360	366	effect	T080	C1280500
28109920	370	383	coronary flow	T042	C0010067
28109920	388	416	immune-suppressive treatment	T061	C0021079
28109920	431	444	characterized	T052	C1880022
28109920	457	468	individuals	T098	C0237401
28109920	492	520	positron emission tomography	T060	C0032743
28109920	523	542	computed tomography	T060	C0040405
28109920	572	581	suspected	T080	C0332147
28109920	582	601	cardiac sarcoidosis	T047	C0392077
28109920	611	635	(18)F-fluorodeoxyglucose	T109,T130	C0046056
28109920	639	648	determine	T080	C0521095
28109920	649	661	inflammation	T046	C0021368
28109920	666	679	(13)N-ammonia	T121,T130	C1998431
28109920	694	712	perfusion deficits	T034	C0428858
28109920	725	733	high-fat	T061	C0521974
28109920	736	757	low-carbohydrate diet	T061	C0259836
28109920	762	775	fasting state	T033	C0015663
28109920	785	793	suppress	T040	C0301625
28109920	794	804	myocardial	T024	C0027061
28109920	805	819	glucose uptake	T043	C1159527
28109920	821	833	Inflammation	T046	C0021368
28109920	838	848	quantified	T081	C1709793
28109920	854	879	standardized uptake value	T081	C2348529
28109920	893	914	myocardial blood flow	T042	C2986786
28109920	934	945	regadenoson	T109,T121	C1698215
28109920	948	958	stimulated	T070	C1948023
28109920	959	968	hyperemia	T047	C0020452
28109920	997	1025	Positron emission tomography	T060	C0032743
28109920	1026	1033	studies	T062	C0008972
28109920	1054	1059	cases	T169	C0868928
28109920	1067	1073	median	T081	C0876920
28109920	1074	1083	follow-up	T058	C1522577
28109920	1091	1096	years	T079	C0439234
28109920	1098	1117	interquartile range	T081	C1711350
28109920	1119	1122	IQR	T081	C1711350
28109920	1135	1140	years	T079	C0439234
28109920	1155	1160	exams	T058	C0582103
28109920	1172	1181	perfusion	T061	C0031001
28109920	1198	1206	regional	T082	C0205147
28109920	1207	1219	inflammation	T046	C0021368
28109920	1221	1226	group	T078	C0441833
28109920	1238	1243	exams	T058	C0582103
28109920	1256	1264	regional	T082	C0205147
28109920	1265	1282	perfusion deficit	T034	C0428858
28109920	1299	1311	inflammation	T046	C0021368
28109920	1313	1318	group	T078	C0441833
28109920	1330	1351	myocardial blood flow	T042	C2986786
28109920	1375	1383	inflamed	T046	C0021368
28109920	1400	1410	myocardium	T024	C0027061
28109920	1419	1425	groups	T078	C0441833
28109920	1442	1445	IQR	T081	C1711350
28109920	1489	1492	IQR	T081	C1711350
28109920	1536	1539	IQR	T081	C1711350
28109920	1583	1586	IQR	T081	C1711350
28109920	1638	1644	median	T081	C0876920
28109920	1645	1654	hyperemic	T047	C0020452
28109920	1655	1677	myocardial blood flows	T042	C2986786
28109920	1716	1724	inflamed	T046	C0021368
28109920	1737	1751	remote regions	T082	C0205147
28109920	1755	1760	group	T078	C0441833
28109920	1785	1788	IQR	T081	C1711350
28109920	1832	1835	IQR	T081	C1711350
28109920	1879	1882	IQR	T081	C1711350
28109920	1926	1929	IQR	T081	C1711350
28109920	1981	1999	Immune-suppression	T061	C0021079
28109920	2022	2034	inflammation	T046	C0021368
28109920	2065	2088	myocardial flow reserve	T201	C1721077
28109920	2090	2093	MFR	T201	C1721077
28109920	2098	2107	follow-up	T058	C1522577
28109920	2117	2120	MFR	T201	C1721077
28109920	2135	2143	worsened	T033	C1457868
28109920	2192	2204	inflammation	T046	C0021368
28109920	2206	2212	median	T081	C0876920
28109920	2215	2218	MFR	T201	C1721077
28109920	2226	2229	IQR	T081	C1711350
28109920	2257	2260	IQR	T081	C1711350
28109920	2303	2310	inverse	T080	C0439850
28109920	2311	2322	correlation	T080	C1707520
28109920	2357	2380	myocardial inflammation	T047	C0027059
28109920	2384	2410	regional myocardial volume	T081	C0449468
28109920	2416	2441	standardized uptake value	T081	C2348529
28109920	2454	2457	MFR	T201	C1721077
28109920	2482	2489	Sarcoid	T047	C0392077
28109920	2500	2523	myocardial inflammation	T047	C0027059
28109920	2545	2564	regional impairment	T169	C0221099
28109920	2568	2588	coronary circulatory	T042	C0010067
28109920	2589	2597	function	T169	C0542341
28109920	2623	2651	immune-suppressive treatment	T061	C0021079
28109920	2676	2699	myocardial inflammation	T047	C0027059
28109920	2715	2735	coronary vasodilator	T121	C0596385
28109920	2736	2744	capacity	T081	C1516240
28109920	2761	2775	adverse effect	T046	C0879626
28109920	2779	2791	inflammation	T046	C0021368
28109920	2795	2815	coronary circulatory	T042	C0010067
28109920	2816	2824	function	T169	C0542341
28109920	2828	2847	cardiac sarcoidosis	T047	C0392077